Introduction
Diabetic foot ulcer (DFU) is the most severe complication of diabetes. Globally, the average prevalence of DFU is 6.3%, with Europe and the Western Pacific region being the most affected areas.1 Amputation and mortality are the most severe outcomes of DFU. Investigations have shown that DFU is the leading cause of non-traumatic amputations worldwide.2 Moreover, recent global meta-analyses revealed 1, 3, and 5-year survival rates of 86.9%, 66.9%, and 50.9% for DFU, with the lowest rates in Europe and the Western Pacific region.3 Patients with DFU face a 30–40 times higher risk of death after amputation than patients with non-ulcerative diabetes.4 Even without amputation, the mortality risk for DFU remains 1.89 times higher than for other patients with diabetes.5 In the USA, 13% of patients with DFU account for 30% of the total healthcare expenditure for diabetes.6
DFU’s occurrence is closely related to diabetic lower extremity complications, primarily diabetic polyneuropathy (DPN) and diabetic peripheral artery disease (DPAD). Other relevant include diabetic dermal lesions, muscle atrophy, etc.7 Implementing a diabetes high-risk foot screening prevention model centered on quickly identifying DPN and DPAD has significantly reduced the risk of DFU.8 However, despite substantial investment, the incidence of DFU has continued to rise in recent years. Therefore, a more refined DFU-centered prevention model is an urgent need, requiring answers to several critical questions, including shared factors among diabetes lower limb complications, factors beyond DPN and DPAD that influence DFU occurrence, and the characteristic distribution of influencing factors for ischemic and non-ischemic DFUs.
Although current research partially addresses these questions, particular diabetes complications, such as diabetic kidney disease, have significantly increased the risk of DFU.9 Nevertheless, due to study limitations in terms of scale, comprehensive measurements have been challenging, given the complex clinical features of the DFU population. As an emerging epidemiological research approach, Mendelian randomization (MR) effectively addresses the issues above. By leveraging genetic variations predating exposure and outcome occurrences, MR minimizes bias caused by selection and achieves results that mimic a randomized controlled trial. By relying on large-scale genome-wide association studies (GWAS) and the robustness of gene variation grouping, MR identifies causal relationships between outcomes and exposure factors by setting reasonable statistical thresholds and selecting instrumental solid variables. Consequently, researchers have used MR to investigate risk factors for various diseases, including diabetes,10 cardiovascular diseases,11 myocardial infarction,12 and cerebrovascular diseases,13 strengthening existing evidence and uncovering previously overlooked potential associations.
In this study, we conducted MR analyses for 85 phenotypes across five categories. By observing causal relationships, we aim to identify potential influencing factors for diabetic lower extremity complications. This study is the first MR study related to DFU, and our findings will provide more reliable evidence for its prevention.